Vectura was established in 1997 to identify and develop opportunities in drug formulation and delivery.  Vectura has evolved into a product development company that focuses on the development of pharmaceutical therapies for airways diseases.


 

2015

Global development and licence agreement with Janssen Biotech (VR096) announced.  Novartis confirm US FDA filing acceptance of NDAs for QVA149 and NVA237. VR942 Phase I Clinical study commenced

2014

AirFluSal® Forspiro® launched in the EU by Sandoz. Vectura acquired Activaero GmbH and raised £52m. Vectura signs a further US collaboration agreement with a leading international pharmaceutical company (existing undisclosed partner for VR315 US) for the VR506 asthma therapy. Novartis submit regulatory applications to US FDA for QVA149 and NVA237

2013

Ultibro® Breezhaler® (QVA149) and Seebri® Breezhaler® (NVA237) launched by Novartis in EU and Japan. Establishment of Kinnovata joint venture in China. Initiated co-development deal with UCB for a novel molecule, VR942. Our partner Sandoz granted first marketing authorisation for AirFluSal® Forspiro® (VR315 EU & ROW) in Denmark

2012

Seebri® Breezhaler® (NVA237) approved in EU and Japan. Novartis announces positive Phase III data for QVA149

2011

Novartis announces positive NVA237 Phase III data and files in Europe and Japan. In August, Vectura licenses VR315 ROW rights to Sandoz and VR315 US rights to an undisclosed partner

2010

Vectura regains US rights to VR315 from Sandoz.  GSK licenses some of Vectura’s dry powder drug formulation patents. Vectura closes laboratory facilities in Nottingham and consolidates formulation activities on the Chippenham site

2009

Vectura's partner Novartis commenced Phase III studies with NVA237 triggering milestone payment and additional milestone payments for VR315 in Europe and US from Sandoz

2008

Vectura and its partners announce positive Phase II data for NVA237. Sandoz was confirmed as partner for the generic asthma/COPD product VR315

2007

Vectura acquired Innovata plc. In July, Vectura moves from AIM to the Official List on the London Stock Exchange

2006

Vectura signed agreement with undisclosed partners for VR315 - EU and US

2005

Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237

2004

Vectura is listed on the London Stock Exchange on AIM

2002

Vectura acquired the Aspirair® inhaler technology and associated device engineering team from Cambridge Consultants Ltd.  Vectura moved to its current head office in Chippenham, Wiltshire, UK

2000

Vectura signed a collaboration with Arakis Ltd (later acquired by Sosei) in the development of AD237 (later NVA237) for the treatment of COPD

1997

Founded by Merlin and then acquired operations from Bath University through issues of shares. Vectura also acquired Co-ordinated Drug Development Limited and the Centre for Drug Formulation Studies. These acquisitions provided formulation expertise, an intellectual property estate, a development services business, and a team of research scientists